Royal DSM NV (DSM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Royal DSM NV (DSM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9888
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Royal DSM NV (DSM) is a science-based company with focus on materials, health and nutrition. It produces vitamins, carotenoids, nutritional lipids and other ingredients; specialty plastics; and fiber and resins solutions. DSM develops materials for medical devices and clean energy from crop residues and bio-chemicals. The company serves customers in animal nutrition and health, packaging and graphic arts, building and construction, pharma solutions, electrical and electronics, automotive, medical, personal care, energy, food, furniture, life protection, beverages and dietary supplements, marine, paint and coatings, manufacturing and equipment, sports, leisure and consumer goods, and textiles and clothing sectors. The company has operations across Eastern Europe, Latin America, North America, Asia, and other regions. DSM is headquartered in Heerlen, the Netherlands.

Royal DSM NV (DSM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Royal DSM NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Royal DSM NV, Medical Devices Deals, 2012 to YTD 2018 10
Royal DSM NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Royal DSM NV, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Verdezyne Raises US$48 Million In Venture Financing 13
Arecor Raises Funds Through Venture Financing 15
Private Equity 16
Bain Capital Private Equity Acquires DSM Sinochem Pharma from Royal DSM and Sinochem Group 16
Partnerships 18
Aerie Pharma Enters into R&D Agreement with Royal DSM 18
OptiBiotix Health Enters into Co-Development Agreement with Royal DSM 19
Royal DSM Forms Joint Venture With JLL Partners 20
Licensing Agreements 22
Aerie Pharma Expands Licensing Agreement with DSM Biomedical 22
Equity Offering 23
Amyris Raises USD50 Million in Second and Final Tranche of Private Placement of Shares 23
Amyris Raises USD47 Million in First Tranche of Private Placement of Shares 25
ChromaDex Completes Private Placement Of Shares For US$3 Million 27
Debt Offering 28
Royal DSM Completes Public Offering Of Bonds Due 2024 For US$684 Million 28
Royal DSM Announces Public Offering Of Notes Due 2019 For US$412.84 Million 29
Royal DSM Completes Private Placement Of Bonds Due 2019 For US$405 Million 30
Acquisition 31
Royal DSM Acquires Amyris Brasil 31
Royal DSM Acquires Biocare Copenhagen 32
i-Health to Acquire UP4 Probiotics from UAS Labs 33
Royal DSM Acquires Aland Nutraceutical 34
DSM Completes Acquisition Of Fortitech, Nutraceutical Company, For US$634 Million 35
Royal DSM Completes Acquisition Of Ocean Nutrition Canada For US$532.7 Million 37
DSM Completes Acquisition Of Kensey Nash, Regenerative Medicine Company, For US$360 Million 39
Royal DSM NV – Key Competitors 41
Royal DSM NV – Key Employees 42
Royal DSM NV – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Joint Venture 46
Recent Developments 48
Strategy And Business Planning 48
Apr 03, 2017: Royal DSM Opens New Biotechnology Center in Delft, the Netherlands 48
Financial Announcements 49
Aug 01, 2018: DSM announces H1 2018 results 49
May 08, 2018: DSM Reports Q1 2018 Results 50
Feb 15, 2018: DSM Reports 2017 Results 51
Nov 02, 2017: DSM Reports Results First Nine Months 2017 58
May 02, 2017: DSM Q1 2017 Results 59
Feb 15, 2017: DSM reports 2016 results 60
Feb 14, 2017: DSM new presentation of accounts as from Q4 2016 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Royal DSM NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Royal DSM NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Royal DSM NV, Deals By Therapy Area, 2012 to YTD 2018 9
Royal DSM NV, Medical Devices Deals, 2012 to YTD 2018 10
Royal DSM NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Verdezyne Raises US$48 Million In Venture Financing 13
Arecor Raises Funds Through Venture Financing 15
Bain Capital Private Equity Acquires DSM Sinochem Pharma from Royal DSM and Sinochem Group 16
Aerie Pharma Enters into R&D Agreement with Royal DSM 18
OptiBiotix Health Enters into Co-Development Agreement with Royal DSM 19
Royal DSM Forms Joint Venture With JLL Partners 20
Aerie Pharma Expands Licensing Agreement with DSM Biomedical 22
Amyris Raises USD50 Million in Second and Final Tranche of Private Placement of Shares 23
Amyris Raises USD47 Million in First Tranche of Private Placement of Shares 25
ChromaDex Completes Private Placement Of Shares For US$3 Million 27
Royal DSM Completes Public Offering Of Bonds Due 2024 For US$684 Million 28
Royal DSM Announces Public Offering Of Notes Due 2019 For US$412.84 Million 29
Royal DSM Completes Private Placement Of Bonds Due 2019 For US$405 Million 30
Royal DSM Acquires Amyris Brasil 31
Royal DSM Acquires Biocare Copenhagen 32
i-Health to Acquire UP4 Probiotics from UAS Labs 33
Royal DSM Acquires Aland Nutraceutical 34
DSM Completes Acquisition Of Fortitech, Nutraceutical Company, For US$634 Million 35
Royal DSM Completes Acquisition Of Ocean Nutrition Canada For US$532.7 Million 37
DSM Completes Acquisition Of Kensey Nash, Regenerative Medicine Company, For US$360 Million 39
Royal DSM NV, Key Competitors 41
Royal DSM NV, Key Employees 42
Royal DSM NV, Other Locations 43
Royal DSM NV, Subsidiaries 43
Royal DSM NV, Joint Venture 46

List of Figures
Royal DSM NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Royal DSM NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Royal DSM NV, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Royal DSM NV (DSM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fresenius Kabi AG:企業の戦略的SWOT分析
    Fresenius Kabi AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Five Prime Therapeutics Inc (FPRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Five Prime Therapeutics Inc (Five Prime) is a clinical state biopharmaceutical company focusing on the research and development of novel treatments for cancer and inflammatory disorders. The company’s developmental pipeline is based on the discovery platform and library of therapeutic protei …
  • Syngen Biotech Co Ltd (8279)-製薬・医療分野:企業M&A・提携分析
    Summary Syngen Biotech Co Ltd (Syngen), a part of Standard Chem& Pharm Co Ltd, is a biotechnology company that specializes in strain identification, micro-organism fermentation, recovery, and purification. The company research, develops, manufactures and distributes active pharmaceutical ingredients …
  • Oman Air (SAOC):企業の戦略・SWOT・財務分析
    Oman Air (SAOC) - Strategy, SWOT and Corporate Finance Report Summary Oman Air (SAOC) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Verastem Inc (VSTM):製薬・医療:M&Aディール及び事業提携情報
    Summary Verastem Inc (Verastem) is a clinical-stage biopharmaceutical company with focus on the discovery, development and commercialization of drugs to treat cancer. The company’s lead product candidates include duvelisib, defactinib (VS-6063), FAK inhibitor (VS-4718) and PI3K/mTOR inhibitor (VS-55 …
  • Inretail Peru Corp.:企業の戦略的SWOT分析
    Inretail Peru Corp. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Celsion Corp (CLSN)-製薬・医療分野:企業M&A・提携分析
    Summary Celsion Corp (Celsion) is an oncology company that focuses on developing a portfolio of new cancer treatments, including directed chemotherapies, RNA based therapies and DNA-mediated immunotherapy. The company’s three platform technologies including Lysolipid Thermally Sensitive Liposomes (L …
  • CITIC Pacific Limited:企業のM&A・事業提携・投資動向
    CITIC Pacific Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CITIC Pacific Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • First Republic Bank:企業のM&A・事業提携・投資動向
    First Republic Bank - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's First Republic Bank Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Bankinter Banca Privada:企業の戦略・SWOT・財務情報
    Bankinter Banca Privada - Strategy, SWOT and Corporate Finance Report Summary Bankinter Banca Privada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Great Wolf Resorts Inc:戦略・SWOT・企業財務分析
    Great Wolf Resorts Inc - Strategy, SWOT and Corporate Finance Report Summary Great Wolf Resorts Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Astronics Corp:企業の戦略・SWOT・財務情報
    Astronics Corp - Strategy, SWOT and Corporate Finance Report Summary Astronics Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Seven Seas Cruises S. DE R.L.:企業の戦略・SWOT・財務情報
    Seven Seas Cruises S. DE R.L. - Strategy, SWOT and Corporate Finance Report Summary Seven Seas Cruises S. DE R.L. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Brookfield Property REIT Inc (GGP):企業の財務・戦略的SWOT分析
    Brookfield Property REIT Inc (GGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Bilfinger SE (GBF):電力:M&Aディール及び事業提携情報
    Summary Bilfinger SE (Bilfinger) is a provider of industrial engineering services. It offers a wide range of services from consulting, construction, manufacturing, plant expansion to maintenance and project management services across diverse end markets. The company’s major service offerings include …
  • Gleiss Lutz Hootz Hirsch GmbH:企業の戦略的SWOT分析
    Gleiss Lutz Hootz Hirsch GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Egmont International Holding AS:企業の戦略的SWOT分析
    Egmont International Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196):企業の財務・戦略的SWOT分析
    Summary Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products include metabolism …
  • Sports Direct International Plc:企業のM&A・事業提携・投資動向
    Sports Direct International Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sports Direct International Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • SoftTech Yazılım Teknolojileri Arastırma Gelistirme ve Pazarlama Ticaret A.S.:企業の戦略・SWOT・財務情報
    SoftTech Yazılım Teknolojileri Arastırma Gelistirme ve Pazarlama Ticaret A.S. - Strategy, SWOT and Corporate Finance Report Summary SoftTech Yazılım Teknolojileri Arastırma Gelistirme ve Pazarlama Ticaret A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆